Agendia, Inc.

156 articles with Agendia, Inc.

• Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project

  6/5/2022

  Agendia, Inc. announced it will present seven posters derived from the company’s FLEX Trial, the real-world, multicenter, prospective, observational breast cancer study at the American Society of Clinical Oncology Annual Meeting 2022.

• Agendia Presents Data at ASCO 2022 Pointing to New Signature ImPrint Immunotherapy Prediction and Expansion of Proprietary Genomic Tests’ Utility to Identify Patients Who Will Benefit Most from Specific Treatments

  6/4/2022

  Agendia, Inc. announced it will share findings in a poster discussion debuting initial data from its ImPrint test, a 53-gene signature in development, at the American Society of Clinical Oncology Annual Meeting 2022.

• Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer

  5/25/2022

  Agendia, Inc., a commercial-stage company focused on improving outcomes for breast cancer patients worldwide by providing physicians and patients with next-generation diagnostic and information solutions to inform optimized treatment decision-making, today announced 10,000 patients have been successfully enrolled in the FLEX Registry.

• Agendia Demonstrates Accessibility and Affordability of MammaPrint® and BluePrint® in Europe at ESMO Breast Cancer 2022

  5/3/2022

  Agendia, Inc. announced that it will present new data at the European Society for Medical Oncology Breast Cancer Congress 2022 taking place in Berlin, Germany on May 3-5, 2022.

• Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment

  2/7/2022

  Agendia, Inc. announced new data published in Genes, Chromosomes and Cancer that show MammaPrint® and BluePrint® gene signatures represent and capture all of the original 10 hallmarks of cancer, recognized as the biological capabilities acquired during the multi-step development of human cancer, as defined by Hanahan and Weinberg.1,2

• Agendia to Provide First Digital MammaPrint Capability to Brazil

  1/12/2022

  Agendia, Inc. announced that it is offering early access to its Digital MammaPrint platform for patients with breast cancer in Brazil, expanding the company’s offerings in the country with the goal of bringing essential information from cancer testing to the larger global breast cancer community.

• Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care

  1/10/2022

  Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, announced a multi-year partnership with Illumina, Inc., to co-develop in vitro diagnostic tests for oncology testing.

• Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors, Strengthening Advisory Group to Support Company Momentum

  1/6/2022

  Agendia, Inc. announced the appointment of healthcare industry veterans Suja Chandrasekaran, MS and Scott Mendel, MBA to the Company’s Board of Directors.

• Agendia Spotlight Poster at SABCS 2021 Confirms Utility of BluePrint® as Biomarker Subtyping Test to Guide Neoadjuvant Chemotherapy Decisions

  12/10/2021

  Agendia, Inc., a world leader in precision oncology for breast cancer, announced that it will present a spotlight poster at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021) which confirms the utility of BluePrint® in guiding neoadjuvant treatment decisions.

• Analysis Presented at SABCS 2021 Confirms MammaPrint® and BluePrint® Predict Outcomes Following Neoadjuvant Chemotherapy

  12/9/2021

  Agendia, Inc., a world leader in precision oncology for breast cancer, today shared data demonstrating the ability of MammaPrint® and BluePrint® to predict patient outcomes following neoadjuvant chemotherapy (NAC) at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021).

• Agendia Presents Data at SABCS 2021 Showing MammaPrint® and BluePrint® More Robustly Identify Genomic Differences in HR+ HER2- Breast Cancers in Black and White Women Beyond Clinical Factors

  12/9/2021

  Agendia Presents Data at SABCS 2021 Showing MammaPrint ® and BluePrint ® More Robustly Identify Genomic Differences in HR+ HER2- Breast Cancers in Black and White Women Beyond Clinical Factors.

• Agendia’s MammaPrint® Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial

  6/7/2021

  MammaPrint was the only test to predict significant 36% and 52% reductions in DFS and BCFI events, respectively, for patients treated with extended endocrine therapy

• Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers

  6/5/2021

  Oral presentation at ASCO 2021 highlights long term data with higher than 99% 8-year breast cancer specific survival for patients with MammaPrint Ultra Low Risk status regardless of clinical risk

• ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer

  6/4/2021

  Transcriptomic differences found between Luminal tumors in African American and non-Hispanic White patients suggest race-associated biology and differences in outcome in breast tumors may result from the effects of structural violence and/or genetic ancestry

• Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations

  6/4/2021

  Whole transcriptome analysis of ER+ breast cancers showed no substantial difference in gene expression between tumors from women younger than 50 and women older than 50 Whole transcriptome analysis confirms that genomic expression profiles from BluePrint ER+ Basal tumors and ER- Basal tumors are very similar, providing clinically actionable information to guide neoadjuvant treatment decisions

• 

  ASCO Update: A Theme of Accessibility and Pricing Plus Individual Reporting

  6/4/2021

  With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.

• Landmark Long-Term Data from EORTC’s MINDACT Study Published in The Lancet Oncology

  3/12/2021

  Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that long-term follow up data from MINDACT, the prospective, randomized trial designed to further confirm the clinical utility of MammaPrint® risk scoring when determining a breast cancer patient’s need for chemotherapy, was published in The Lancet Oncology, and can be viewed online here.

• Data Presented at the Miami Breast Cancer Conference Show MammaPrint® and BluePrint® Accurately Predict Pathologic Complete Response Rate Regardless of Age

  3/4/2021

  Results support use of Agendia’s genomic tests to better tailor pre-operative treatment and timing for surgery

• Agendia to Participate in the Cowen 41st Annual Healthcare Conference

  2/25/2021

  Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the Cowen 41st Annual Healthcare Conference, which takes place March 1-4, 2021.

• Agendia to Participate in the 39th Annual J.P. Morgan Healthcare Conference

  1/11/2021

  Agendia to Participate in the 39 th Annual J.P. Morgan Healthcare Conference